Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

F080 - Complementary, Natural and Novel Dermatology Therapeutics: An Evidence-based Perspective

Saturday, February 17; 3:30 PM - 5:30 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Recognize diseases where complementary therapies are utilized.
  • Describe common complementary and natural therapies that are used.
  • Select complementary treatments and interventions with the best evidence for use with an emphasis on randomized controlled trials.

Description

This session provides a broad introduction to complementary and natural therapies for multiple common dermatological conditions. We will review literature and studies for the evidence of efficacy for warts, acne, atopic dermatitis, itch, and for skin aging. The target audience is practitioners of all levels interested in learning more about the evidence for complementary therapies for incorporation into dermatological practice.

Disclosures

  • Draelos, Zoe Diana, MD: Abbott Laboratories – I(Grants/Research Funding); Actavis – I(Grants/Research Funding); AGI Dermatics – I(Grants/Research Funding); Allergan, Inc. – I(Grants/Research Funding); AmDerma Pharmaceuticals, LLC – I(Grants/Research Funding); Amgen – I(Grants/Research Funding); Amneal Pharmaceuticals, LLC – I(Grants/Research Funding); AstraZeneca – I(Grants/Research Funding); Avon Products, Inc. – I(Grants/Research Funding); Bayer – I(Grants/Research Funding); Bayer Consumer Healthcare Pharmaceuticals – I(Grants/Research Funding); Beiersdorf, Inc. – I(Grants/Research Funding); Boots – C(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding); Chattem, Inc. – I(Grants/Research Funding); Colgate-Palmolive – I(Grants/Research Funding); Dermira – I(Grants/Research Funding); Dial Corporation – I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding); Elizabeth Arden – I(Grants/Research Funding); Exeltis – I(Grants/Research Funding); Galderma Laboratories, L.P. – I(Grants/Research Funding); GlaxoSmithKline – I(Grants/Research Funding); Glenmark Generics Inc. – I(Grants/Research Funding); Guthy-Renker – I(Grants/Research Funding); Helix BioMedix – I(Grants/Research Funding); Johnson & Johnson Consumer Products Company – I(Grants/Research Funding); Kao Brands – I(Grants/Research Funding); Kimberly Clark – I(Grants/Research Funding); Kythera – I(Grants/Research Funding); L'Oreal USA Inc. – I(Grants/Research Funding); La Roche-Posay Laboratoire Pharmaceutique – I(Grants/Research Funding); Lexington International LLC – I(Grants/Research Funding); Living Proof, Inc – I(Grants/Research Funding); Lumity – I(Grants/Research Funding); MakuCell, Inc. – I(Grants/Research Funding); Maruho Co., Ltd – I(Grants/Research Funding); Medicis Pharmaceutical Corporation – I(Grants/Research Funding); Merck & Co., Inc. – I(Grants/Research Funding); Merz Pharmaceuticals, LLC – I(Grants/Research Funding); Mimetica Pty. Limited – I(Grants/Research Funding); Neocutis – I(Grants/Research Funding); Neutrogena Corporation – I(Grants/Research Funding); Niadyne – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Nuskin – I(Grants/Research Funding); Oculus – I(Grants/Research Funding); Onset Therapeutics – I(Grants/Research Funding); Otsuka Pharmaceutical Co., Ltd. – I(Grants/Research Funding); Pacific Biosciences – I(Grants/Research Funding); Perrigo Company – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Procter & Gamble Company – I(Grants/Research Funding); Promius Pharma, LLC – I(Grants/Research Funding); Quinnova Pharmaceuticals, Inc. – I(Grants/Research Funding); Ranbaxy Laboratories Limited – I(Grants/Research Funding); RECKITT BENCKISER (ESPAÑA), S.L. – I(Grants/Research Funding); Revance Therapeutics, Inc. – I(Grants/Research Funding); Revision Skincare – I(Grants/Research Funding); Signum Biosciences, Inc. – I(Grants/Research Funding); SkinMedica, Inc. – I(Grants/Research Funding); Sun Products Corporation – I(Grants/Research Funding); Suneva Medical, Inc. – I(Grants/Research Funding); Symrise – I(Grants/Research Funding); Syneron, Inc. – I(Grants/Research Funding); Taro Pharm – I(Grants/Research Funding); Teva Pharmaceuticals USA – I(Grants/Research Funding); Tolmar – I(Grants/Research Funding); Valeant Pharmaceuticals International – I(Grants/Research Funding); Vichy Laboratoires – I(Grants/Research Funding);
  • Graber, Emmy M., MD, MBA: 3Derm Systems – C(H); Allergan, Inc – A(H); Almirall – C(H); Castle Creek Pharmaceuticals – C(H); Sol-Gel Technologies – C(H);
  • Lio, Peter A., MD: AbbVie – C(Fees); Anacor Pharmaceuticals, Inc. – A(H); AOBiome, LLC – I(Grants/Research Funding); DermTap, Inc. – A(SO); Exeltis – C(Fees); Ferndale Laboratories, Inc. – SP(H); Franklin BioScience – C(SO); Galderma Laboratories, L.P. – SP(Fees); Galderma Laboratories, LP – C(Fees); Heel (Biologische Heilmittel Heel GmbH) – C(Fees); IntraDerm Pharmaceuticals – A(H); Johnson & Johnson Consumer Products Company – A(H), C(Fees), SP(Fees); Kiniksa Pharmaceuticals, Ltd. – I(Grants/Research Funding); L'Oreal USA Inc. – C(H); La Fondation pour la Dermatite Atopique (Foundation for Atopic Dermatitis – I(Grants/Research Funding); La Roche-Posay Laboratorie Pharmaceutique – SP(H); Menlo Therapeutics – A(H); Mission – Speaker/Faculty Education(H); Modernizing Medicine – A(NC), SH(SO); National Eczema Association – A(NC); Odeza LLC – C(SO); Pfizer Inc. – SP(H); Pierre Fabre Dermatologie – SP(H); Realm Therapeutics – A(H); Regeneron – A(Fees), SP(Fees); Sanofi US Services – A(H); Syncere Skin Systems – A(SO); Theraplex – C(Fees); Valeant Pharmaceuticals International – C(Fees); Valeant Pharmaceuticals North America LLC – SP(H);
  • Shi, Vivian, MD: Dermveda – SH(SO); Menlo Therapeutics – A(Fees); National Eczema Association – O(Fees); Novartis – Speaker/Faculty Education(NC);
  • Sivamani, Raja, MD: DermVeda – A(NC);
  • Yosipovitch, Gil, MD: Galderma Laboratories, L.P. – A(H); Kiniksa Pharmaceuticals, Ltd. – I(Grants/Research Funding); Menlo Therapeutics – A(H), I(Grants/Research Funding); Novartis – C(H); OPKO Health, Inc – C(H); Pfizer Inc. – A(H), I(Grants/Research Funding); Sanofi/Regeneron – A(H); Sienna Biopharmaceuticals – A(H); Sun Pharmaceutical Industries Ltd. – I(Grants/Research Funding); Trevi Therapeutics – A(H);
Schedule
Saturday, February 17
3:30 PM
Dr. Sivamani / Intro to Complementary Therapies
3:35 PM
Dr. Graber / Acne
3:55 PM
Dr. Lio / Warts
4:15 PM
Dr. Shi / Atopic Dermatitis
4:35 PM
Dr. Yosipovitch / Itch
4:55 PM
Dr. Draelos / Skin Aging and Cosmetics
5:15 PM
All faculty / Q & A Session
Event Details
  • Date
    Saturday, February 17
  • Time
    3:30 PM - 5:30 PM
  • Location
    Room 30B
  • CME Credits
    2.00
  • Type
Directors/Co-Directors
  • Raja Sivamani, MD, FAAD
Speakers
  • Emmy M. Graber, MD, MBA, FAAD
  • Gil Yosipovitch, MD
  • Peter A. Lio, MD, FAAD
  • Vivian Shi, MD, FAAD
  • Zoe Diana Draelos, MD, FAAD - Handout